STANO-PHARM 50

Stanozolol Injection 50 mg /1 ml

Pharma

Description

STANO-PHARM 50 Stanozolol Injection 50 mg/ 1 ml) is a white suspension for Intramuscular use. Each 1ml contains Stanozolol 50 mg.

Pharmacodynamics

 Anabolic steroids are synthetic derivatives of Testosterone. Stanozolol has been found to increase low-density lipoproteins and decrease high-density lipoproteins. These changes are not associated with any increase in total cholesterol or triglyceride levels and revert to normal on discontinuation of treatment. Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a deficient or non-functional C1 esterase inhibitor (C1 INH) and clinically characterized by episodes of swelling of the face, extremities, genitalia, bowel wall, and upper respiratory tract. In small clinical studies, Stanozolol was effective in controlling the frequency and severity of attacks of angioedema and in increasing serum levels of C 1 INH and C4. Stanozolol is not effective in stopping HAE attacks while they are under way. The effect of Stanozolol on increasing serum levels of C1 INH and C4 may be related to an increase in protein anabolism.

Indications and Usage

Hereditary Angioedema: Stanozolol is indicated prophylactically to decrease the frequency and severity of attacks of angioedema

Dosage and Administration

The use of anabolic steroids may be associated with serious adverse reactions, many of which are dose related:

Therefore patients should be placed on the lowest possible effective dose. Stanozolol has been given by intramuscular injection in doses of 50 mg to 100mg every 1 or 3 times per week. The prophylactic dose of Stanozolol to be used prior to dental extraction or other traumatic or stressful situations has not been established and may be substantially larger.

Adverse effects

 Hepatic: Cholestatic jaundice with rarely, hepatic necrosis and death. Hepatocellular neoplasm’s and peliosis hepatis have been reported in association with long term androgenic anabolic steroid. Reversible changes in liver function tests also occur including increased bromsulphalein (BSP) retention and increases in serum bilirubin, glutamic oxaloacetic transaminase (SGOT), and alkaline phosphatase.

Genitourinary System:

 In men, Prepubertal: Phallic enlargement and increased frequency of erections

 Postpubertal: Inhibition of testicular functions, testicular atrophy and oligospermia, impotence, chronic priapism,epididymitis and bladder irritability.

In women: Clitoral enlargement, menstrual irregularities.

In both sexes: increased or decreased libido.

CNS: Habituation, excitation, insomnia, and depression.

Gastrointestinal: Nausea, vomiting. diarrhea.

Hematologic: Bleeding in patients on concomitant anticoagulant therapy.

Breast: Gynecomastia.

Larynx: Deepening of the voice in women.

Hair: Hirsutism and male pattern baldness in women.

Skin: Acne (especially in women and prepubertal boys.)

Skelelal: Premature closure of epiphyses in children.

Fluid and Electrolytes: Edema, retention of serum electrolytes (Sodium, chloride, potassium, phosphate, and calcium).

Overdose

An overdose of this medication is unlikely to threaten health. Symptoms of Stanozolol overdose are not known.

Storage

Store in cool dry place below 25°C. Protect from light.

Packing

5 ampoules are packed in a plastic tray along with pack insert.

Markeled by

PRO PHARMA